| We have research collaborations with leading
pharmaceutical and biotechnology companies
that include the design, creation and
optimization of drug candidates across
a broad range of therapeutic areas.
Selected Collaborators:
 |
|
|
| |
Target Classes |
|
|
| |
GPCRs,
Kinases, Nuclear Receptors,
PDEs, Proteases, Allosteric
Regulators |
|
|
|
|
|
|
|
|
| |
Multiple Therapeutic
Areas |
|
|
| |
CNS, Cancer,
Cardiovascular, Diabetes,
Pulmonary Disease,
Inflammatory Disease |
|
|
|
|
|
Featured Collaboration – Eli Lilly and Company – IC83 / LY2603618 / CHK-1 Program
We entered into a collaboration agreement with ICOS Corporation in 1999 to create small molecule CHK-1 inhibitors. Array and ICOS scientists invented IC83 / LY2603618, and Array received a milestone payment after the first patient was dosed with this molecule in a Phase 1 clinical trial in early 2007. The agreement provided research funding, which has now ended, and Array is entitled to receive additional milestone payments based on Eli Lilly’s achievement of clinical milestones. Eli Lilly acquired ICOS in 2007.
|
